Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Laser zaps sweat glands in tiny hyperhidrosis trial

NCT ID NCT04178161

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested a laser treatment for people with excessive sweating (hyperhidrosis). The approach used a dye to mark sweat glands, then a special laser to destroy them. Only 2 people were enrolled, and the study was terminated early, so we have very little data on whether it works or is safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Laser treatment (fractional erbium laser) combined with methylene blue iontophoresis
What this could lead to
If it works, this could point toward a minimally invasive treatment for excessive sweating without long-term medication.
What could go wrong
This was a very early, tiny trial (only 2 participants) that was terminated, so results are extremely limited. The procedure may not be effective or safe for broader use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

2 people

The number who actually took part.

Started

Sep 2016

Finished

May 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects of ages between 18 and 65 years. 2. Subjects with any Fitzpatrick skin type. 3. Subjects who are proficient in the English language. 4. Willingness to participate in the study. 5. Willingness to undergo experimental procedure. 6. Informed consent agreement signed by the subject. 7. Willingness to follow the follow-up schedule. 8. Willingness not to use any other hyperhidrosis treatment to the tests sites during the study period (i.e. deodorant, at-home iontophoresis, Botox, MiraDry). 9. Patient rates symptoms at level "3" or "4" on the hyperhidrosis disease severity scale (HDSS, see below). 10. Subject in appropriate physical health to ride a stationary bicycle to the point of eliciting sweat. 11. No known allergy to iodine or potato starch Exclusion Criteria: 1. Pregnancy 2. Subjects on systemic treatment for hyperhidrosis, such as anticholinergic drugs (e.g. glycopyrrolate), sedatives or tranquilizers, within the past 8 weeks. 3. Subjects who have undergone surgical excision of sweat glands or sympathectomy for hyperhidrosis. 4. Subjects with an underlying disorder, such as neurologic injury or disease affecting the autonomic system, vascular disorders and metabolic disorders (e.g. hyperthyroidism, diabetes mellitus) that can produce hyperhidrosis 5. Subjects with a history of coronary artery disease. 6. Subjects with a history of poor compliance or psychosis 7. Subjects taking SSRIs, SNRIs, TCAs, or MAOIs 8. Subjects with known hypersensitivity to methylene blue 9. Subjects with cardiac pacemaker or any other electrically powered implantable device. 10. Subjects not proficient in the English language. 11. Subject not in appropriate physical health to ride a stationary bicycle to the point of eliciting sweat. 12. Known allergy to iodine or potato starch.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperhidrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Massachusetts General Hospital - Wellman Center for Photomedicine

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.